News

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
Novavax has been available since 2022 through a pandemic-era Emergency Use Authorization. A decision on full approval – which ...
The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...